These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38136326)

  • 1. Prognostic Factors of Platinum-Refractory Advanced Urothelial Carcinoma Treated with Pembrolizumab.
    Akashi Y; Yamamoto Y; Hashimoto M; Adomi S; Fujita K; Kiba K; Minami T; Yoshimura K; Hirayama A; Uemura H
    Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of second progression-free survival in patients with advanced urothelial cancer who received platinum-based combination chemotherapy followed by pembrolizumab.
    Sato R; Inamoto T; Matsushita Y; Takemura A; Uchimoto T; Sano A; Tanaka H; Ishikawa G; Watanabe K; Watanabe H; Tamura K; Motoyama D; Sugiyama T; Otsuka A; Harada KI; Azuma H; Miyake H
    Int J Urol; 2023 Sep; 30(9):730-736. PubMed ID: 36575640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of pre-treatment risk stratification and post-treatment neutrophil/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma.
    Yamamoto Y; Yatsuda J; Shimokawa M; Fuji N; Aoki A; Sakano S; Yamamoto M; Suga A; Tei Y; Yoshihiro S; Kitahara S; Nagao K; Takai K; Kamiryo Y; Akao J; Yamaguchi S; Oba K; Shimabukuro T; Matsumoto H; Kamba T; Matsuyama H
    Int J Clin Oncol; 2021 Jan; 26(1):169-177. PubMed ID: 32948925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project.
    Rizzo A; Monteiro FSM; Ürün Y; Massari F; Park SH; Bourlon MT; Poprach A; Rizzo M; Takeshita H; Giannatempo P; Soares A; Roviello G; Molina-Cerrillo J; Carrozza F; Abahssain H; Messina C; Kopp RM; Pichler R; Formisano L; Tural D; Atzori F; Calabrò F; Kanesvaran R; Buti S; Santoni M
    Target Oncol; 2024 Sep; 19(5):747-755. PubMed ID: 39107651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy.
    Lindner AK; Lackner F; Tymoszuk P; Barth DA; Seeber A; Kocher F; Toth B; Hochleitner M; Pichler M; Pichler R
    Biol Sex Differ; 2023 Jun; 14(1):38. PubMed ID: 37277835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical Practice.
    Furubayashi N; Kuroiwa K; Tokuda N; Tomoda T; Morokuma F; Hori Y; Negishi T; Inoue T; Kumagai M; Nakamura M
    J Clin Med Res; 2020 May; 12(5):300-306. PubMed ID: 32489505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study.
    Li JR; Wang SS; Lu K; Chen CS; Cheng CL; Hung SC; Chiu KY; Hsu CY; Yang CK
    Anticancer Res; 2023 Mar; 43(3):1331-1339. PubMed ID: 36854504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort.
    Ito K; Kobayashi T; Kojima T; Hikami K; Yamada T; Ogawa K; Nakamura K; Sassa N; Yokomizo A; Abe T; Tsuchihashi K; Tatarano S; Inokuchi J; Tomida R; Fujiwara M; Takahashi A; Matsumoto K; Shimizu K; Araki H; Kurahashi R; Osaki Y; Tashiro Y; Uegaki M; Ogawa O; Kitamura H; Nishiyama H
    Cancer Med; 2021 May; 10(10):3188-3196. PubMed ID: 33931987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
    Massari F; Santoni M; Takeshita H; Okada Y; Tapia JC; Basso U; Maruzzo M; Scagliarini S; Büttner T; Fornarini G; Myint ZW; Galli L; Souza VC; Pichler R; De Giorgi U; Gandur N; Lam ET; Gilbert D; Popovic L; Grande E; Mammone G; Berardi R; Crabb SJ; Kemp R; Molina-Cerrillo J; Freitas M; Luz M; Iacovelli R; Calabrò F; Tural D; Atzori F; Küronya Z; Chiari R; Campos S; Caffo O; Fay AP; Kucharz J; Zucali PA; Rinck JA; Zeppellini A; Bastos DA; Aurilio G; Mota A; Trindade K; Ortega C; Sade JP; Rizzo M; Fiala O; Vau N; Giannatempo P; Barillas A; Monteiro FSM; Dauster B; Mennitto A; Nogueira L; de Carvalho Fernandes R; Seront E; Aceituno LG; Grillone F; Cutuli HJ; Fernandez M; Bassanelli M; Kopp RM; Roviello G; Abahssain H; Procopio G; Milella M; Kopecky J; Martignetti A; Messina C; Caitano M; Inman E; Kanesvaran R; Herchhorn D; Santini D; Bamias A; Bisonni R; Mosca A; Morelli F; Maluf F; Soares A; Nunes F; Pinto A; Zgura A; Incorvaia L; Ansari J; Zabalza IO; Landmesser J; Rizzo A; Mollica V; Marchetti A; Rosellini M; Sorgentoni G; Battelli N; Buti S; Porta C; Bellmunt J
    Cancer Immunol Immunother; 2024 Apr; 73(6):106. PubMed ID: 38634928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status.
    Grivas P; Plimack ER; Balar AV; Castellano D; O'Donnell PH; Bellmunt J; Powles T; Hahn NM; de Wit R; Bajorin DF; Ellison MC; Frenkl TL; Godwin JL; Vuky J
    Eur Urol Oncol; 2020 Jun; 3(3):351-359. PubMed ID: 32423837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
    Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
    JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower neutrophil-to-lymphocyte ratio and positive programmed cell death ligand-1 expression are favorable prognostic markers in patients treated with pembrolizumab for urothelial carcinoma.
    Miyama Y; Kaneko G; Nishimoto K; Yasuda M
    Cancer Med; 2022 Nov; 11(22):4236-4245. PubMed ID: 35699000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice.
    Tamura D; Jinnouchi N; Abe M; Ikarashi D; Matsuura T; Kato R; Maekawa S; Kato Y; Kanehira M; Takata R; Obara W
    Int J Clin Oncol; 2020 May; 25(5):899-905. PubMed ID: 31907720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study.
    Qiang H; Lei Y; Shen Y; Li J; Zhong H; Zhong R; Zhang X; Chang Q; Lu J; Feng H; Zhu Y; Addeo A; Banna GL; Oh IJ; Qian J; Chu T
    Transl Lung Cancer Res; 2022 Jan; 11(1):87-99. PubMed ID: 35242630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study.
    Giannatempo P; Raggi D; Marandino L; Bandini M; Farè E; Calareso G; Colecchia M; Gallina A; Ross JS; Alessi A; Briganti A; Montorsi F; Madison R; Necchi A
    Ann Oncol; 2020 Dec; 31(12):1764-1772. PubMed ID: 32979512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment Hemoglobin Levels and Platelet-to-Lymphocyte Ratio Predict Survival Benefit from Pembrolizumab in Advanced Urothelial Carcinoma.
    Kurashina R; Ando K; Inoue M; Maruyama R; Mitani K; Takenobu H; Haruta M; Onuki R; Matsuoka Y; Kamijo T; Kageyama Y
    Cancer Diagn Progn; 2023; 3(2):230-235. PubMed ID: 36875313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Performance Status on Oncologic Outcomes in Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitor: A Systematic Review and Meta-analysis.
    Kawada T; Yanagisawa T; Mostafaei H; Sari Motlagh R; Quhal F; Rajwa P; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pallauf M; Pradere B; Teoh JY; Karakiewicz PI; Araki M; Shariat SF
    Eur Urol Focus; 2023 Mar; 9(2):264-274. PubMed ID: 36774273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Model of Baseline Medications plus Neutrophil-to-lymphocyte Ratio in Patients with Advanced Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitor plus Platinum Doublet: A Multicenter Retrospective Study.
    Nasu I; Kondo M; Uozumi R; Takada S; Nawata S; Iihara H; Okumura Y; Takemoto M; Mino K; Sasaki T; Hirose C; Aomori T; Shimano R; Maeno K; Oizumi S; Kusumoto S; Ohno Y; Ikemura S; Takai D; Hara A; Kawazoe H; Nakamura T
    J Cancer; 2023; 14(5):676-688. PubMed ID: 37056385
    [No Abstract]   [Full Text] [Related]  

  • 20. The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.
    Bambury RM; Benjamin DJ; Chaim JL; Zabor EC; Sullivan J; Garcia-Grossman IR; Regazzi AM; Ostrovnaya I; Apollo A; Xiao H; Voss MH; Iyer G; Bajorin DF; Rosenberg JE
    Oncologist; 2015 May; 20(5):508-15. PubMed ID: 25845990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.